Fondazione Epatocentro Ticino
8
5
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Swiss Primary Sclerosing Cholangitis Cohort Study
Role: lead
The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland
Role: lead
Swiss Autoimmune Hepatitis Cohort Study
Role: lead
Methylene Blue Treatment of Chronic Hepatitis B Virus Infection
Role: lead
Methylene Blue Treatment of COVID-19
Role: lead
Swiss Primary Biliary Cholangitis Cohort Study
Role: lead
Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease
Role: lead
Reducing the Burden of Influenza After Solid-Organ Transplantation
Role: collaborator
All 8 trials loaded